Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, 52074, Germany.
Cell Death Dis. 2022 Aug 13;13(8):704. doi: 10.1038/s41419-022-05137-5.
Ferroptosis is a novel type of programmed cell death that differs from apoptosis in that it involves iron-dependent peroxidation of membrane phospholipids. Its role in a variety of human disorders, including cancer has been hypothesized in recent years. While it may function as an endogenous tumor suppressor in a variety of cancers, its role during initiation and progression of liver cancer, particularly hepatocellular carcinoma (HCC), is yet unknown. Because HCC is most commonly found in chronically injured livers, we utilized two well-established mouse models of chronic injury-dependent HCC formation: Treatment with streptozotocin and high-fat diet as metabolic injury model, as well as treatment with diethylnitrosamine and carbon tetrachloride as toxic injury model. We used mice with hepatocyte-specific deletion of Acsl4, a key mediator of ferroptosis, to explore the significance of ferroptotic cell death in hepatocytes, the cell type of origin for HCC. Surprisingly, preventing ferroptotic cell death in hepatocytes by deleting Acsl4 does not increase the formation of HCC. Furthermore, Acsl4-deficient livers display less fibrosis and proliferation, especially in the HCC model of toxic damage. Intriguingly, in this model, the absence of ACSL4-dependent processes such as ferroptosis significantly slow down the growth of HCC. These findings suggest that during HCC formation in a chronically injured liver, ferroptotic cell death is not an endogenous tumor-suppressive mechanism. Instead, we find that ACSL4-dependent processes have an unanticipated cancer-promoting effect during HCC formation, which is most likely due to aggravated liver damage as demonstrated by increased hepatic fibrosis. Previous studies suggested that ferroptosis might have beneficial effects for patients during HCC therapy. As a result, during HCC progression and therapy, ferroptosis may have both cancer-promoting and cancer-inhibitory effects, respectively.
铁死亡是一种新型的程序性细胞死亡方式,与细胞凋亡不同,它涉及膜磷脂的铁依赖性过氧化。近年来,人们假设它在包括癌症在内的多种人类疾病中发挥作用。虽然在多种癌症中,铁死亡可能作为一种内源性肿瘤抑制因子发挥作用,但它在肝癌(尤其是肝细胞癌,HCC)的发生和发展中的作用尚不清楚。由于 HCC 最常发生在慢性损伤的肝脏中,我们利用两种已建立的慢性损伤依赖性 HCC 形成的小鼠模型:链脲佐菌素和高脂肪饮食作为代谢损伤模型,以及二乙基亚硝胺和四氯化碳作为毒性损伤模型。我们使用肝细胞特异性敲除 Acsl4 的小鼠(铁死亡的关键介质)来探索铁死亡细胞死亡在肝癌的起源细胞-肝细胞中的意义。令人惊讶的是,通过敲除 Acsl4 来阻止铁死亡细胞死亡并不会增加 HCC 的形成。此外,Acsl4 缺陷的肝脏显示出较少的纤维化和增殖,尤其是在毒性损伤的 HCC 模型中。有趣的是,在这种模型中,缺乏 ACSL4 依赖性过程(如铁死亡)显著减缓 HCC 的生长。这些发现表明,在慢性损伤的肝脏中形成 HCC 时,铁死亡细胞死亡不是一种内源性的肿瘤抑制机制。相反,我们发现 ACSL4 依赖性过程在 HCC 形成过程中具有意外的促进癌症的作用,这很可能是由于肝脏纤维化增加导致的肝损伤加重所致。先前的研究表明,铁死亡可能对 HCC 治疗的患者有益。因此,在 HCC 进展和治疗期间,铁死亡可能分别具有促进癌症和抑制癌症的作用。